EP3082817A4 - Compositions for drug administration - Google Patents

Compositions for drug administration Download PDF

Info

Publication number
EP3082817A4
EP3082817A4 EP14872645.8A EP14872645A EP3082817A4 EP 3082817 A4 EP3082817 A4 EP 3082817A4 EP 14872645 A EP14872645 A EP 14872645A EP 3082817 A4 EP3082817 A4 EP 3082817A4
Authority
EP
European Patent Office
Prior art keywords
compositions
drug administration
administration
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14872645.8A
Other languages
German (de)
French (fr)
Other versions
EP3082817A1 (en
Inventor
Edward T. Maggio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aegis Therapeutics LLC
Original Assignee
Aegis Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/133,350 external-priority patent/US9895444B2/en
Application filed by Aegis Therapeutics LLC filed Critical Aegis Therapeutics LLC
Publication of EP3082817A1 publication Critical patent/EP3082817A1/en
Publication of EP3082817A4 publication Critical patent/EP3082817A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
EP14872645.8A 2013-12-18 2014-12-17 Compositions for drug administration Withdrawn EP3082817A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/133,350 US9895444B2 (en) 2004-08-25 2013-12-18 Compositions for drug administration
PCT/US2014/070944 WO2015095389A1 (en) 2013-12-18 2014-12-17 Compositions for drug administration

Publications (2)

Publication Number Publication Date
EP3082817A1 EP3082817A1 (en) 2016-10-26
EP3082817A4 true EP3082817A4 (en) 2017-06-21

Family

ID=53403653

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14872645.8A Withdrawn EP3082817A4 (en) 2013-12-18 2014-12-17 Compositions for drug administration

Country Status (2)

Country Link
EP (1) EP3082817A4 (en)
WO (1) WO2015095389A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
CN107583039A (en) 2012-01-09 2018-01-16 阿道恰公司 PH is 7 and the Injectable solution at least containing the PI basal insulins for being 5.8 to 8.5 and substitution copolymerization (amino acid)
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
US10383918B2 (en) 2016-06-07 2019-08-20 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a statistical co-polyamino acid
CN110139651A (en) * 2016-11-18 2019-08-16 欧邦特制药公司 For treating the excessive composition of opioid and method
WO2019110836A1 (en) 2017-12-07 2019-06-13 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
WO2019110837A1 (en) 2017-12-07 2019-06-13 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
FR3083087A1 (en) 2018-06-29 2020-01-03 Adocia COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINOACID
CN111670042A (en) 2017-12-07 2020-09-15 阿道恰公司 Compositions in the form of injectable aqueous solutions comprising human glucagon and a polyamino acid copolymer
US20190275110A1 (en) 2017-12-07 2019-09-12 Adocia Compositions in the form of an injectale aqueous solution comprising human glucagon and a co-polyamino acid
PL3678649T3 (en) * 2018-02-06 2023-05-08 Aegis Therapeutics, Llc Intranasal epinephrine formulations and methods for the treatment of disease
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
FR3067247A1 (en) 2018-06-07 2018-12-14 Adocia COMPOSITIONS IN THE FORM OF AN INJECTION AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINOACID
EA202091615A1 (en) 2018-12-21 2021-03-05 Аегис Терапьютикс, Ллс INTRANASAL FORMULATIONS BASED ON EPINEPHRINE AND METHODS FOR TREATING THE DISEASE
US10653690B1 (en) * 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
US10729687B1 (en) * 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
IL297658A (en) 2020-05-18 2022-12-01 Orexo Ab Pharmaceutical composition for drug delivery

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076506A1 (en) * 1999-06-16 2000-12-21 Nastech Pharmaceutical Co., Inc. Pharmaceutical formulations and methods comprising intranasal morphine
WO2004054542A2 (en) * 2002-12-13 2004-07-01 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
US20060045868A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608073B1 (en) * 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
US8440631B2 (en) * 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
EP2747563A4 (en) * 2011-08-26 2015-06-24 Aegis Therapeutics Llc Compositions and methods thereof for oral administration of drugs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076506A1 (en) * 1999-06-16 2000-12-21 Nastech Pharmaceutical Co., Inc. Pharmaceutical formulations and methods comprising intranasal morphine
WO2004054542A2 (en) * 2002-12-13 2004-07-01 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
US20060045868A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAVIS S S ET AL: "ABSORPTION ENHANCERS FOR NASAL DRUG DELIVERY", CLINICAL PHARMACOKINETICS, ADIS INTERNATIONAL LTD., AUCKLAND, NZ, vol. 42, no. 13, 1 January 2003 (2003-01-01), pages 1107 - 1128, XP009040612, ISSN: 0312-5963, DOI: 10.2165/00003088-200342130-00003 *
EDWARD T MAGGIO: "Intravail: highly effective intranasal delivery of peptide and protein drugs", EXPERT OPINION ON DRUG DELIVERY, INFORMA HEALTHCARE, GB, vol. 3, no. 4, 1 July 2006 (2006-07-01), pages 529 - 539, XP008152448, ISSN: 1742-5247, DOI: 10.1517/17425247.3.4.529 *
EDWARD T. MAGGIO ET AL: "High efficiency intranasal drug delivery using Intravail alkylsaccharide absorption enhancers", DRUG DELIVERY AND TRANSLATIONAL RESEARCH, vol. 3, no. 1, 12 May 2012 (2012-05-12), Germany, pages 16 - 25, XP055370902, ISSN: 2190-393X, DOI: 10.1007/s13346-012-0069-z *
See also references of WO2015095389A1 *

Also Published As

Publication number Publication date
WO2015095389A1 (en) 2015-06-25
EP3082817A1 (en) 2016-10-26

Similar Documents

Publication Publication Date Title
IL288961A (en) Pharmaceutical compositions
EP3082817A4 (en) Compositions for drug administration
EP3089736A4 (en) Pharmaceutical compositions for poorly water-soluble compounds
PL2943181T3 (en) Pharmaceutical compositions
EP4005604B8 (en) Delivery of drugs
EP3077006A4 (en) Polymer-carbohydrate conjugates for drug delivery technology
HK1212899A1 (en) Pharmaceutical compositions comprising everolimus (everolimus)
ZA201401683B (en) Pharmaceutical compositions for rectal administration
ZA201408333B (en) Pharmaceutical compositions
EP2990039A4 (en) Solid pharmaceutical composition
EP3087987A4 (en) Pharmaceutical composition containing palonosetron
EP3003324A4 (en) Pharmaceutical compositions
HK1231390A1 (en) Pharmaceutical composition for topical administration
EP3020417A4 (en) Pharmaceutical composition for respiratory administration
TWI800759B (en) Pharmaceutical dosage forms
EP3043648A4 (en) Bendamustine pharmaceutical compositions
EP3041478A4 (en) Vaccine compositions for drug addiction
EP3003369A4 (en) Pharmaceutical compositions comprising pyrophosphate
HRP20171888T1 (en) Pharmaceutical compositions
HUP1300496A2 (en) Stable pharmaceutical composition
EP3006033A4 (en) Anticancer drug
EP3082783A4 (en) Stable oral pharmaceutical composition
EP2992890A4 (en) Pharmaceutical composition
EP3065746A4 (en) Therapeutic compositions
EP2979698A4 (en) Pharmaceutical composition for oral administration

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160614

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170522

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/04 20060101ALI20170516BHEP

Ipc: A61K 47/26 20060101ALI20170516BHEP

Ipc: A61K 31/485 20060101AFI20170516BHEP

Ipc: A61K 9/00 20060101ALI20170516BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20191008

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AEGIS THERAPEUTICS, LLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20211201